7 research outputs found
Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma (Annals of Hematology, (2020), 99, 8, (1793-1804), 10.1007/s00277-020-04149-5)
Low-resolution figures were inadvertently created during production and published. These have been replaced with the high-resolution figures that were originally provided by the authors. No changes have been made to the data presented within the figures or to any other manuscript content.Please see below for the high-resolution figures:. © 2020, Springer-Verlag GmbH Germany, part of Springer Nature